Australia's Job Market Holds Firm in March 2026 with Strong Full-Time Hiring 
IMF Warns Middle East War to Deepen Economic Divide Across Latin America and Caribbean 
Trump Administration Settles Lawsuit Barring Federal Agencies from Pressuring Social Media Censorship 
Will a new border deal with the US open a backdoor into Kiwis’ personal data? 
Federal Judge Blocks Pentagon's Blacklisting of AI Company Anthropic 
Justice Jackson Slams Supreme Court's Growing Use of Shadow Docket 
China's New Home Prices Continue to Fall in March Despite Signs of Recovery in Major Cities 
Judge Blocks DOJ Subpoenas in Federal Reserve Investigation, Delaying Powell Succession 
Oil Prices Plunge as Strait of Hormuz Reopens Amid U.S.-Iran Ceasefire Talks 
Asian Currencies Hold Steady Amid Iran Peace Talks and BOJ Rate Hike Uncertainty 
Chile's Kast Unveils 40-Point Economic Reform Package to Boost Growth 
CK Hutchison's Panama Ports Dispute Escalates as Arbitration Claims Surpass $2 Billion 
Middle East Ceasefire Hopes Lift Asian Markets as Oil Prices Retreat 
U.S. Crude Oil Exports Surge Toward Record Highs Amid Global Supply Crisis 
Oil Prices Dip as Middle East Peace Hopes Grow Amid Iran-U.S. Talks 
FEMA Reinstates $1 Billion Disaster Prevention Grant Program After Court Order 
Johnson & Johnson disclosed that it spent $800 million in settling "substantially all" of the roughly 9,000 cases by men who claimed having developed excessive breast tissue in using the company's antipsychotic drug Risperdal.
The company said it reached the agreement with lawyers handling the cases, including a lawsuit in Philadelphia by Maryland resident Nicholas Murray, who was awarded an $8 billion in punitive damage by a jury award in 2019. A judge has since reduced the award to $6.8 million.
The lawsuits, filed in Pennsylvania, California, and Missouri, generally accused J&J of failing to warn of the risk called gynecomastia associated with Risperdal, which they claimed were marketed for off-label, unapproved uses with children.
The company denied the allegations.
In 1993, the US Food and Drug Administration approved Risperdal for treating schizophrenia and bipolar mania in adults. It was only in 2006 that it was approved for treating irritability associated with autism in children.
The company separately agreed in 2013 to pay $2.2 billion to settle US criminal and civil probes into its marketing of Risperdal and two other drugs.
In May, the US Supreme Court rejected J&J's bid to overturn a $70 million jury verdict against it for its failure to warn about risks associated with using Risperdal.
